Special Issue "Liquid Biopsy for Clinical Application"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (28 February 2017).
Dr. William Chi-shing Cho
Queen Elizabeth Hospital, Hong Kong, China
Interests: cancer biomarker; chinese medicine; diabetes mellitus; evidence-based medicine; genomics; microRNA; molecular diagnostics; nasopharyngeal carcinoma; non-small cell lung cancer; proteomics
In parallel to conventional biopsy and cytology, studies of liquid biopsy provide a non-invasive means for the diagnosis, prognosis and treatment response prediction of diseases. A variety of body fluids are used in clinical analyses, including plasma, serum, pleural effusion, sputum and urine. For example, we can monitor EGFR T790M with plasma DNA from lung cancer patients; predict the prognosis of breast cancer patients by measuring the number of circulating tumor cells/mL in plasma, as well as analyze tumor DNA in urine for patients with non-muscle invasive bladder cancer. Furthermore, advancements in molecular analysis of circulating tumor cells enable measurement down to the single-cell level and some applications are ready to be used in clinical studies.
With the advance of technologies, sensitive detection and application of liquid biopsy has emerged in every medical field. Thus, I would like to call upon high quality work on this important area to shape our current understanding and management of various diseases.
This Special Issue particularly focuses on how liquid biopsy offers solutions to clinical applications, thereby eventually providing accurate diagnoses and prescribing the right drug and right treatment to the right patient.
Original papers and review articles that focus on the latest advances of liquid biopsy are welcome in the following and associated key areas:
- Circulating cell-free nucleic acids for cancer diagnosis, prognosis and treatment monitoring
- Circulating cell-free DNA that reflects epigenetic regulation
- Circulating tumor cells as surrogate markers for systemic cancer
- Liquid biopsy for cancer screening, patient stratification and monitoring
- Liquid biopsy for the detection of actionable oncogenic mutations in human cancers
- Application of next-generation sequencing in liquid biopsy
- Development of liquid biopsy platforms for the early detection of cancer
- Liquid biopsy for protein subtyping
- Urine for disease and drug screening
- Applications for therapeutic drug monitoring and toxicology
Dr. William Chi-shing Cho
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.